Impact of early and delayed azvudine administration on COVID-19 mortality: a retrospective study

DOI record: { "DOI": "10.1038/s41598-025-05381-7", "ISSN": [ "2045-2322" ], "URL": "http://dx.doi.org/10.1038/s41598-025-05381-7", "alternative-id": [ "5381" ], "article-number": "21729", "assertion": [ { "group": { "label": "Article History", "name": "ArticleHistory" }, "label": "Received", "name": "received", "order": 1, "value": "14 August 2024" }, { "group": { "label": "Article History", "name": "ArticleHistory" }, "label": "Accepted", "name": "accepted", "order": 2, "value": "2 June 2025" }, { "group": { "label": "Article History", "name": "ArticleHistory" }, "label": "First Online", "name": "first_online", "order": 3, "value": "1 July 2025" }, { "group": { "label": "Declarations", "name": "EthicsHeading" }, "name": "Ethics", "order": 1 }, { "group": { "label": "Ethics approval and consent to participate", "name": "EthicsHeading" }, "name": "Ethics", "order": 2, "value": "This study was approved by the Institutional Review Board of Peking Union Medical College Hospital (I-23PJ946). As this was a retrospective study, the requirement for informed consent was waived by Institutional Review Board of Peking Union Medical College Hospital." }, { "group": { "label": "Competing interests", "name": "EthicsHeading" }, "name": "Ethics", "order": 3, "value": "The authors declare no competing interests." } ], "author": [ { "affiliation": [], "family": "Wang", "given": "Luo", "sequence": "first" }, { "affiliation": [], "family": "Wang", "given": "Yaqi", "sequence": "additional" }, { "affiliation": [], "family": "Xu", "given": "Yan", "sequence": "additional" }, { "affiliation": [], "family": "Fan", "given": "Junping", "sequence": "additional" }, { "affiliation": [], "family": "Pan", "given": "Siqi", "sequence": "additional" }, { "affiliation": [], "family": "Xie", "given": "Huaiya", "sequence": "additional" }, { "affiliation": [], "family": "Zhang", "given": "Ting", "sequence": "additional" }, { "affiliation": [], "family": "Chen", "given": "Ruxuan", "sequence": "additional" }, { "affiliation": [], "family": "Liu", "given": "Xiaoyan", "sequence": "additional" }, { "affiliation": [], "family": "Shi", "given": "Chuan", "sequence": "additional" }, { "affiliation": [], "family": "Zhou", "given": "Qing", "sequence": "additional" }, { "affiliation": [], "family": "Shi", "given": "Yuequan", "sequence": "additional" }, { "affiliation": [], "family": "Cheng", "given": "Chongsheng", "sequence": "additional" }, { "affiliation": [], "family": "Dai", "given": "Lu", "sequence": "additional" }, { "affiliation": [], "family": "Zhang", "given": "Haoran", "sequence": "additional" }, { "affiliation": [], "family": "Wu", "given": "Aohua", "sequence": "additional" }, { "affiliation": [], "family": "Liu", "given": "Xueqi", "sequence": "additional" }, { "affiliation": [], "family": "Zhang", "given": "Hong", "sequence": "additional" }, { "affiliation": [], "family": "Wang", "given": "Jinglan", "sequence": "additional" }, { "affiliation": [], "family": "Du", "given": "Bin", "sequence": "additional" }, { "affiliation": [], "family": "Liu", "given": "Jihai", "sequence": "additional" }, { "affiliation": [], "family": "Zhu", "given": "Huadong", "sequence": "additional" }, { "affiliation": [], "family": "Ma", "given": "Xiaojun", "sequence": "additional" }, { "affiliation": [], "family": "Huang", "given": "Jing", "sequence": "additional" }, { "affiliation": [], "family": "Tian", "given": "Xinlun", "sequence": "additional" }, { "affiliation": [], "family": "Wang", "given": "Mengzhao", "sequence": "additional" }, { "affiliation": [], "family": "Zhang", "given": "Shuyang", "sequence": "additional" } ], "container-title": "Scientific Reports", "container-title-short": "Sci Rep", "content-domain": { "crossmark-restriction": false, "domain": [ "link.springer.com" ] }, "created": { "date-parts": [ [ 2025, 7, 1 ] ], "date-time": "2025-07-01T18:38:47Z", "timestamp": 1751395127000 }, "deposited": { "date-parts": [ [ 2025, 7, 1 ] ], "date-time": "2025-07-01T18:38:49Z", "timestamp": 1751395129000 }, "funder": [ { "award": [ "2021-I2M-1-048" ], "name": "Chinese Academy of Medical Sciences Innovation Fund for Medical Sciences" }, { "award": [ "2023YFC3041900" ], "name": "National Key Research and Development Program of China" }, { "award": [ "2023-PUMCH-G-001" ], "name": "National High Level Hospital Clinical Research Funding" } ], "indexed": { "date-parts": [ [ 2025, 7, 1 ] ], "date-time": "2025-07-01T19:10:05Z", "timestamp": 1751397005388, "version": "3.41.0" }, "is-referenced-by-count": 0, "issue": "1", "issued": { "date-parts": [ [ 2025, 7, 1 ] ] }, "journal-issue": { "issue": "1", "published-online": { "date-parts": [ [ 2025, 12 ] ] } }, "language": "en", "license": [ { "URL": "https://creativecommons.org/licenses/by-nc-nd/4.0", "content-version": "tdm", "delay-in-days": 0, "start": { "date-parts": [ [ 2025, 7, 1 ] ], "date-time": "2025-07-01T00:00:00Z", "timestamp": 1751328000000 } }, { "URL": "https://creativecommons.org/licenses/by-nc-nd/4.0", "content-version": "vor", "delay-in-days": 0, "start": { "date-parts": [ [ 2025, 7, 1 ] ], "date-time": "2025-07-01T00:00:00Z", "timestamp": 1751328000000 } } ], "link": [ { "URL": "https://www.nature.com/articles/s41598-025-05381-7.pdf", "content-type": "application/pdf", "content-version": "vor", "intended-application": "text-mining" }, { "URL": "https://www.nature.com/articles/s41598-025-05381-7", "content-type": "text/html", "content-version": "vor", "intended-application": "text-mining" }, { "URL": "https://www.nature.com/articles/s41598-025-05381-7.pdf", "content-type": "application/pdf", "content-version": "vor", "intended-application": "similarity-checking" } ], "member": "297", "original-title": [], "prefix": "10.1038", "published": { "date-parts": [ [ 2025, 7, 1 ] ] }, "published-online": { "date-parts": [ [ 2025, 7, 1 ] ] }, "publisher": "Springer Science and Business Media LLC", "reference": [ { "key": "5381_CR1", "unstructured": "WHO COVID-19 Dashboard. Geneva: World Health Organization, 2020  (2023). https://covid19.who.int/" }, { "DOI": "10.1002/jmv.27643", "author": "D Tian", "doi-asserted-by": "publisher", "first-page": "2376", "journal-title": "J. Med. Virol.", "key": "5381_CR2", "unstructured": "Tian, D., Sun, Y., Xu, H. & Ye, Q. The emergence and epidemic characteristics of the highly mutated SARS-CoV-2 Omicron variant. J. Med. Virol. 94, 2376–2383. https://doi.org/10.1002/jmv.27643 (2022).", "volume": "94", "year": "2022" }, { "DOI": "10.1002/jmv.28138", "author": "Y Zhou", "doi-asserted-by": "publisher", "first-page": "e28138", "journal-title": "J. Med. Virol.", "key": "5381_CR3", "unstructured": "Zhou, Y., Zhi, H. & Teng, Y. The outbreak of SARS-CoV-2 Omicron lineages, immune escape, and vaccine effectivity. J. Med. Virol. 95, e28138. https://doi.org/10.1002/jmv.28138 (2023).", "volume": "95", "year": "2023" }, { "key": "5381_CR4", "unstructured": "Joint prevention and control Mechnism of The State Council for the Novel Coronavirus Pneumonia. Notice on further optimizing and implementing the prevention and control measures of the novel coronavirus (2022). http://www.gov.cn/xinwen/2022-12/07/content_5730443.htm" }, { "DOI": "10.3390/molecules29235564", "doi-asserted-by": "publisher", "key": "5381_CR5", "unstructured": "Barghash, R. F. et al. Navigating the COVID-19 therapeutic landscape: unveiling novel perspectives on FDA-Approved medications, vaccination targets, and emerging novel strategies. Molecules. 29 https://doi.org/10.3390/molecules29235564 (2024)." }, { "DOI": "10.3390/coatings11111273", "author": "RF Barghash", "doi-asserted-by": "publisher", "first-page": "1273", "journal-title": "Coatings", "key": "5381_CR6", "unstructured": "Barghash, R. F. et al. In Silico modeling as a perspective in developing potential vaccine candidates and therapeutics for COVID-19. Coatings. 11, 1273 (2021).", "volume": "11", "year": "2021" }, { "DOI": "10.1136/bmj.m3379", "author": "F Lamontagne", "doi-asserted-by": "publisher", "first-page": "m3379", "journal-title": "BMJ", "key": "5381_CR7", "unstructured": "Lamontagne, F. et al. A living WHO guideline on drugs for covid-19. BMJ. 370, m3379. https://doi.org/10.1136/bmj.m3379 (2020).", "volume": "370", "year": "2020" }, { "DOI": "10.1016/j.lanwpc.2022.100602", "author": "AK Wai", "doi-asserted-by": "publisher", "first-page": "100602", "journal-title": "Lancet Reg. Health West. Pac.", "key": "5381_CR8", "unstructured": "Wai, A. K. et al. Association of molnupiravir and Nirmatrelvir-Ritonavir with preventable mortality, hospital admissions and related avoidable healthcare system cost among high-risk patients with mild to moderate COVID-19. Lancet Reg. Health West. Pac. 30, 100602. https://doi.org/10.1016/j.lanwpc.2022.100602 (2023).", "volume": "30", "year": "2023" }, { "DOI": "10.1016/s1473-3099(22)00507-2", "author": "CKH Wong", "doi-asserted-by": "publisher", "first-page": "1681", "journal-title": "Lancet Infect. Dis.", "key": "5381_CR9", "unstructured": "Wong, C. K. H. et al. Real-world effectiveness of early molnupiravir or nirmatrelvir-ritonavir in hospitalised patients with COVID-19 without supplemental oxygen requirement on admission during Hong kong’s Omicron BA.2 wave: a retrospective cohort study. Lancet Infect. Dis. 22, 1681–1693. https://doi.org/10.1016/s1473-3099(22)00507-2 (2022).", "volume": "22", "year": "2022" }, { "DOI": "10.1016/s0140-6736(22)01586-0", "author": "CKH Wong", "doi-asserted-by": "publisher", "first-page": "1213", "journal-title": "Lancet", "key": "5381_CR10", "unstructured": "Wong, C. K. H. et al. Real-world effectiveness of molnupiravir and nirmatrelvir plus Ritonavir against mortality, hospitalisation, and in-hospital outcomes among community-dwelling, ambulatory patients with confirmed SARS-CoV-2 infection during the Omicron wave in Hong kong: an observational study. Lancet 400, 1213–1222. https://doi.org/10.1016/s0140-6736(22)01586-0 (2022).", "volume": "400", "year": "2022" }, { "DOI": "10.1016/j.xinn.2022.100321", "author": "B Yu", "doi-asserted-by": "publisher", "first-page": "100321", "journal-title": "Innov. (Camb)", "key": "5381_CR11", "unstructured": "Yu, B. & Chang, J. The first Chinese oral anti-COVID-19 drug azvudine launched. Innov. (Camb). 3, 100321. https://doi.org/10.1016/j.xinn.2022.100321 (2022).", "volume": "3", "year": "2022" }, { "key": "5381_CR12", "unstructured": "Diagnosis and treatment protocol for COVID-19 in China. (trial version 10). (2023). https://www.gov.cn/zhengce/zhengceku/2023-01/06/content_5735343.htm" }, { "DOI": "10.1002/advs.202001435", "author": "Z Ren", "doi-asserted-by": "publisher", "first-page": "e2001435", "journal-title": "Adv. Sci. (Weinh)", "key": "5381_CR13", "unstructured": "Ren, Z. et al. Open-Label, controlled clinical trial of azvudine tablets in the treatment of mild and common COVID-19, a pilot study. Adv. Sci. (Weinh). 7, e2001435. https://doi.org/10.1002/advs.202001435 (2020). A Randomized.", "volume": "7", "year": "2020" }, { "DOI": "10.1038/s41392-021-00835-6", "author": "JL Zhang", "doi-asserted-by": "publisher", "first-page": "414", "journal-title": "Signal. Transduct. Target. Ther.", "key": "5381_CR14", "unstructured": "Zhang, J. L. et al. Azvudine is a thymus-homing anti-SARS-CoV-2 drug effective in treating COVID-19 patients. Signal. Transduct. Target. Ther. 6, 414. https://doi.org/10.1038/s41392-021-00835-6 (2021).", "volume": "6", "year": "2021" }, { "DOI": "10.1002/jmv.28756", "author": "G Deng", "doi-asserted-by": "publisher", "first-page": "e28756", "journal-title": "J. Med. Virol.", "key": "5381_CR15", "unstructured": "Deng, G. et al. Real-world effectiveness of azvudine versus nirmatrelvir-ritonavir in hospitalized patients with COVID-19: A retrospective cohort study. J. Med. Virol. 95, e28756. https://doi.org/10.1002/jmv.28756 (2023).", "volume": "95", "year": "2023" }, { "DOI": "10.1016/j.eclinm.2023.101981", "author": "Y Sun", "doi-asserted-by": "publisher", "first-page": "101981", "journal-title": "EClinicalMedicine", "key": "5381_CR16", "unstructured": "Sun, Y. et al. Oral azvudine for hospitalised patients with COVID-19 and pre-existing conditions: a retrospective cohort study. EClinicalMedicine. 59, 101981. https://doi.org/10.1016/j.eclinm.2023.101981 (2023).", "volume": "59", "year": "2023" }, { "DOI": "10.1056/NEJMoa2204919", "author": "R Arbel", "doi-asserted-by": "publisher", "first-page": "790", "journal-title": "N. Engl. J. Med.", "key": "5381_CR17", "unstructured": "Arbel, R. et al. Nirmatrelvir use and severe Covid-19 outcomes during the Omicron surge. N. Engl. J. Med. 387, 790–798. https://doi.org/10.1056/NEJMoa2204919 (2022).", "volume": "387", "year": "2022" }, { "DOI": "10.1056/NEJMoa2118542", "author": "J Hammond", "doi-asserted-by": "publisher", "first-page": "1397", "journal-title": "N. Engl. J. Med.", "key": "5381_CR18", "unstructured": "Hammond, J. et al. Oral nirmatrelvir for High-Risk, nonhospitalized adults with Covid-19. N. Engl. J. Med. 386, 1397–1408. https://doi.org/10.1056/NEJMoa2118542 (2022).", "volume": "386", "year": "2022" }, { "DOI": "10.1093/cid/ciac600", "author": "H Li", "doi-asserted-by": "publisher", "first-page": "e148", "journal-title": "Clin. Infect. Dis.", "key": "5381_CR19", "unstructured": "Li, H. et al. Association of nirmatrelvir/ritonavir treatment on upper respiratory severe acute respiratory syndrome coronavirus 2 reverse Transcription-Polymerase chain reaction (SARS-Cov-2 RT-PCR) negative conversion rates among High-Risk patients with coronavirus disease 2019 (COVID-19). Clin. Infect. Dis. 76, e148–e154. https://doi.org/10.1093/cid/ciac600 (2023).", "volume": "76", "year": "2023" }, { "DOI": "10.1093/cid/ciac180", "author": "LD Saravolatz", "doi-asserted-by": "publisher", "first-page": "165", "journal-title": "Clin. Infect. Dis.", "key": "5381_CR20", "unstructured": "Saravolatz, L. D., Depcinski, S. & Sharma, M. Molnupiravir and Nirmatrelvir-Ritonavir: oral coronavirus disease 2019 antiviral drugs. Clin. Infect. Dis. 76, 165–171. https://doi.org/10.1093/cid/ciac180 (2023).", "volume": "76", "year": "2023" }, { "DOI": "10.1056/NEJMoa2116846", "author": "RL Gottlieb", "doi-asserted-by": "publisher", "first-page": "305", "journal-title": "N. Engl. J. Med.", "key": "5381_CR21", "unstructured": "Gottlieb, R. L. et al. Early Remdesivir to prevent progression to severe Covid-19 in outpatients. N. Engl. J. Med. 386, 305–315. https://doi.org/10.1056/NEJMoa2116846 (2022).", "volume": "386", "year": "2022" }, { "key": "5381_CR22", "unstructured": "Common Terminology Criteria for Adverse Events (CTCAE). Version 5.0, < (2017). https://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_5x7.pdf." }, { "DOI": "10.1016/j.cellsig.2020.109721", "author": "R Poduri", "doi-asserted-by": "publisher", "first-page": "109721", "journal-title": "Cell. Signal.", "key": "5381_CR23", "unstructured": "Poduri, R., Joshi, G. & Jagadeesh, G. Drugs targeting various stages of the SARS-CoV-2 life cycle: exploring promising drugs for the treatment of Covid-19. Cell. Signal. 74, 109721. https://doi.org/10.1016/j.cellsig.2020.109721 (2020).", "volume": "74", "year": "2020" }, { "DOI": "10.1016/j.apsb.2024.03.032", "author": "N Sheng", "doi-asserted-by": "publisher", "first-page": "3140", "journal-title": "Acta Pharm. Sin B", "key": "5381_CR24", "unstructured": "Sheng, N. et al. Selectively T cell phosphorylation activation of azvudine in the thymus tissue with immune protection effect. Acta Pharm. Sin B. 14, 3140–3154. https://doi.org/10.1016/j.apsb.2024.03.032 (2024).", "volume": "14", "year": "2024" }, { "DOI": "10.1038/s41573-023-00672-y", "author": "G Li", "doi-asserted-by": "publisher", "first-page": "449", "journal-title": "Nat. Rev. Drug Discov", "key": "5381_CR25", "unstructured": "Li, G., Hilgenfeld, R., Whitley, R. & De Clercq, E. Therapeutic strategies for COVID-19: progress and lessons learned. Nat. Rev. Drug Discov. 22, 449–475. https://doi.org/10.1038/s41573-023-00672-y (2023).", "volume": "22", "year": "2023" }, { "DOI": "10.1038/s41594-021-00651-0", "author": "F Kabinger", "doi-asserted-by": "publisher", "first-page": "740", "journal-title": "Nat. Struct. Mol. Biol.", "key": "5381_CR26", "unstructured": "Kabinger, F. et al. Mechanism of molnupiravir-induced SARS-CoV-2 mutagenesis. Nat. Struct. Mol. Biol. 28, 740–746. https://doi.org/10.1038/s41594-021-00651-0 (2021).", "volume": "28", "year": "2021" }, { "DOI": "10.1038/s41598-024-74502-5", "author": "H Xie", "doi-asserted-by": "publisher", "first-page": "23974", "journal-title": "Sci. Rep.", "key": "5381_CR27", "unstructured": "Xie, H. et al. Effectiveness and safety of azvudine versus nirmatrelvir-ritonavir in adult patients infected with COVID-19 Omicron strains: a retrospective study in Beijing. Sci. Rep. 14, 23974. https://doi.org/10.1038/s41598-024-74502-5 (2024).", "volume": "14", "year": "2024" }, { "DOI": "10.1016/j.jhazmat.2024.137071", "author": "V Chandrasekar", "doi-asserted-by": "publisher", "first-page": "137071", "journal-title": "J. Hazard. Mater.", "key": "5381_CR28", "unstructured": "Chandrasekar, V., Mohammad, S., Aboumarzouk, O., Singh, A. V. & Dakua, S. P. Quantitative prediction of toxicological points of departure using two-stage machine learning models: A new approach methodology (NAM) for chemical risk assessment. J. Hazard. Mater. 487, 137071. https://doi.org/10.1016/j.jhazmat.2024.137071 (2025).", "volume": "487", "year": "2025" }, { "DOI": "10.2174/0115734110316443240725051037", "doi-asserted-by": "publisher", "key": "5381_CR29", "unstructured": "Singh, A. et al. Investigating tattoo pigments composition with UV-Vis and FT-IR spectroscopy supported by chemometric modelling. Curr. Anal. Chem. 20 https://doi.org/10.2174/0115734110316443240725051037 (2024)." }, { "DOI": "10.1056/NEJMoa2002032", "author": "WJ Guan", "doi-asserted-by": "publisher", "first-page": "1708", "journal-title": "N. Engl. J. Med.", "key": "5381_CR30", "unstructured": "Guan, W. J. et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl. J. Med. 382, 1708–1720. https://doi.org/10.1056/NEJMoa2002032 (2020).", "volume": "382", "year": "2020" }, { "DOI": "10.1136/bmj.m1985", "doi-asserted-by": "publisher", "key": "5381_CR31", "unstructured": "Docherty, A. B. et al. Features of 20 133 UK patients in hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: prospective observational cohort study. BMJ. 369, m1985. https://doi.org/10.1136/bmj.m1985 (2020)." }, { "DOI": "10.1016/s2213-2600(24)00179-6", "author": "MMI Meslé", "doi-asserted-by": "publisher", "first-page": "714", "journal-title": "Lancet Respir Med.", "key": "5381_CR32", "unstructured": "Meslé, M. M. I. et al. Estimated number of lives directly saved by COVID-19 vaccination programmes in the WHO European region from december, 2020, to march, 2023: a retrospective surveillance study. Lancet Respir Med. 12, 714–727. https://doi.org/10.1016/s2213-2600(24)00179-6 (2024).", "volume": "12", "year": "2024" }, { "DOI": "10.1017/ash.2022.253", "author": "Y Markovskaya", "doi-asserted-by": "publisher", "first-page": "e114", "journal-title": "Antimicrob. Steward Healthc. Epidemiol.", "key": "5381_CR33", "unstructured": "Markovskaya, Y., Gavioli, E. M., Cusumano, J. A. & Glatt, A. E. Coronavirus disease 2019 (COVID-19): secondary bacterial infections and the impact on antimicrobial resistance during the COVID-19 pandemic. Antimicrob. Steward Healthc. Epidemiol. 2, e114. https://doi.org/10.1017/ash.2022.253 (2022).", "volume": "2", "year": "2022" }, { "DOI": "10.1186/s13063-024-07914-3", "author": "X Tian", "doi-asserted-by": "publisher", "first-page": "77", "journal-title": "Trials", "key": "5381_CR34", "unstructured": "Tian, X. et al. Efficacy and safety of azvudine in symptomatic adult COVID-19 participants who are at increased risk of progressing to critical illness: a study protocol for a multicentre randomized double-blind placebo-controlled phase III trial. Trials 25, 77. https://doi.org/10.1186/s13063-024-07914-3 (2024).", "volume": "25", "year": "2024" }, { "DOI": "10.1016/s0140-6736(07)61602-x", "author": "E von Elm", "doi-asserted-by": "publisher", "first-page": "1453", "journal-title": "Lancet", "key": "5381_CR35", "unstructured": "von Elm, E. et al. The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet 370, 1453–1457. https://doi.org/10.1016/s0140-6736(07)61602-x (2007).", "volume": "370", "year": "2007" }, { "DOI": "10.21037/atm.2018.12.10", "author": "Z Zhang", "doi-asserted-by": "publisher", "first-page": "16", "journal-title": "Ann. Transl. Med.", "key": "5381_CR36", "unstructured": "Zhang, Z., Kim, H. J., Lonjon, G. & Zhu, Y. Balance diagnostics after propensity score matching. Ann. Transl Med. 7, 16. https://doi.org/10.21037/atm.2018.12.10 (2019).", "volume": "7", "year": "2019" }, { "DOI": "10.1080/03610910902859574", "author": "PC Austin", "doi-asserted-by": "publisher", "first-page": "1228", "journal-title": "Commun. Stat. Simul. Comput.", "key": "5381_CR37", "unstructured": "Austin, P. C. Using the standardized difference to compare the prevalence of a binary variable between two groups in observational research. Commun. Stat. Simul. Comput. 38, 1228–1234. https://doi.org/10.1080/03610910902859574 (2009).", "volume": "38", "year": "2009" } ], "reference-count": 37, "references-count": 37, "relation": {}, "resource": { "primary": { "URL": "https://www.nature.com/articles/s41598-025-05381-7" } }, "score": 1, "short-title": [], "source": "Crossref", "subject": [], "subtitle": [], "title": "Impact of early and delayed azvudine administration on COVID-19 mortality: a retrospective study", "type": "journal-article", "update-policy": "https://doi.org/10.1007/springer_crossmark_policy", "volume": "15" }